Remove Biopharma Remove Pharmaceutical Remove Pharmaceutical products Remove Safety
article thumbnail

Automation to accelerate biopharma in next decade

European Pharmaceutical Review

A report on automation in the biopharma industr y has shown that the market is projected to grow at a compound annual growth rate (CAGR) of 5.7 Factors impacting the automation in the biopharma industry market The report found that 75 percent of pharmaceutical organisations want to use automated solutions more frequently.

article thumbnail

Astellas Drug Acquired in $5.9B Deal Wins FDA Approval in Vision-Loss Disorder

MedCity News

The regulatory decision comes as safety concerns emerge around the first therapy for the disease, an Apellis Pharmaceuticals product. Izervay, a drug developed by Astellas Pharma subsidiary Iveric Bio, is now the second approved therapy for the degenerative vision-loss disorder geographic atrophy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

These molecules of interest also impacted the pharmaceutical industry, and pharmaceutical companies faced a requirement to rapidly adopt risk mitigation plans to monitor the presence of nitrosamines in drug products. However, this regulatory ban does not impact active pharmaceutical ingredients (APIs).

article thumbnail

Practical advice for Early Scientific Advice (ESA) in HTA submissions

pharmaphorum

In recent years, the biopharma market has become progressively complex. As a result, payers are feeling increased pressure to make the right decisions based on the perceived value of each product. HTA agencies can assist biopharma companies at the early stages of development to ensure they are meeting the expectations of payers.